The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

Earlier this year, Summit Therapeutics and Akeso unveiled new data on their PD-1/VEGF-A bispecific drug, ivonescimab, showing ...

BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Trump Taps Matt Gaetz for Attorney General, a Provocative Move President-elect Trump plans to nominate the Florida congressman, among a flurry of personnel announcements as Republicans neared ...

Former Democratic congresswoman Tulsi Gabbard has been appointed as the director of national intelligence by US President-elect Donald Trump. Gabbard, who switched to the Republican Party, is a ...

Mom of 3 was brutally tortured before being set ablaze in Manipur: Autopsy A horrifying incident in Manipur's Jiribam district has left the community reeling after a 31-year-old mother of three ...

Mediterranean chain Cava raised full-year outlook as well. Q3 sales jumped 39%, accelerating from Q2's pace. Shares of Cava ...